The University of Texas MD Anderson Cancer Center and Varian today announced a new strategic collaboration to develop an integrated software platform to streamline review of radiation oncology treatment plans.
The goal of the platform is to establish an efficient framework to connect participating sites to a central database, allowing MD Anderson physicians to host collaborative review sessions around treatment plans and to communicate...
The North Texas A Conversation With a Living Legend® will honor Los Angeles Dodgers starting pitcher Clayton Kershaw in an interview with...
The University of Texas MD Anderson Cancer Center today opened its newest free-standing facility in The Woodlands. Serving patients in The...
Abstract: LBA32
The three-drug combination of encorafenib, binimetinib and cetuximab significantly improved overall survival (OS) in patients with BRAF-mutated metastatic colorectal cancer (mCRC), according to results of the BEACON CRC Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
The treatment combination resulted in median OS of 9 months for the combination therapy compared...
Abstract: LBA3
Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that initial treatment...
In the largest smoking cessation study of cancer patients to date, researchers from The University of Texas MD Anderson Cancer Center...
Pegilodecakin, a first-in-class drug currently in clinical trials, has shown positive safety results and may offer a potential new treatment...
The University of Texas MD Anderson Cancer Center has awarded Sheryl Harris, C.N.A., the Julie and Ben Rogers Award for Excellence in Patient...
The University of Texas MD Anderson Cancer Center goes gold for Kick Childhood Cancer Awareness Night at BBVA Stadium, Saturday, Sept. 21...
The University of Texas MD Anderson Cancer Center extends deepest sympathy to family and friends of philanthropist and energy...